Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
Clinical Trials Arena on MSN10d
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trialDaiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
J.P. Morgan analyst Seiji Wakao maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on March 5 and set a price target ...
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...
Our collaboration with Daiichi Sankyo is an exciting opportunity to unlock therapeutic access to new cell types, paving the way for precision treatments that can transform patient outcomes.” ...
On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback